$1.69
1.81% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US00972D1054
Symbol
AKBA
Sector
Industry

Akebia Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

Akebia Therapeutics, Inc. Classifications & Recommendation:

Buy
100%

Akebia Therapeutics, Inc. Price Target

Target Price $5.50
Price $1.69
Potential
Number of Estimates 3
3 Analysts have issued a price target Akebia Therapeutics, Inc. 2025 . The average Akebia Therapeutics, Inc. target price is $5.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 3 analysts: 3 Analysts recommend Akebia Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Akebia Therapeutics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Akebia Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 194.62 172.00
33.46% 11.62%
Net Margin -30.20% -29.70%
19.08% 1.66%

3 Analysts have issued a sales forecast Akebia Therapeutics, Inc. 2024 . The average Akebia Therapeutics, Inc. sales estimate is

$172m
Unlock
. This is
1.43% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$178m 1.72%
Unlock
, the lowest is
$162m 7.22%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $195m 33.46%
2024
$172m 11.62%
Unlock
2025
$178m 3.22%
Unlock
2026
$246m 38.81%
Unlock
2027
$350m 42.12%
Unlock
2028
$485m 38.44%
Unlock

3 Akebia Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Akebia Therapeutics, Inc. net profit estimate is

$-51.1m
Unlock
. This is
21.66% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-33.6m 20.00%
Unlock
, the lowest is
$-69.3m 65.01%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-58.8m 46.15%
2024
$-51.1m 13.10%
Unlock
2025
$-53.9m 5.48%
Unlock
2026
$31.5m 158.44%
Unlock
2027
$92.4m 193.33%
Unlock
2028
$190m 105.68%
Unlock

Net Margin

2023 -30.20% 19.08%
2024
-29.70% 1.66%
Unlock
2025
-30.35% 2.19%
Unlock
2026
12.78% 142.11%
Unlock
2027
26.37% 106.34%
Unlock
2028
39.18% 48.58%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.28 -0.24
46.15% 14.29%
P/E negative
EV/Sales 2.44

3 Analysts have issued a Akebia Therapeutics, Inc. forecast for earnings per share. The average Akebia Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.24
Unlock
. This is
20.00% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.16 20.00%
Unlock
, the lowest is
$-0.33 65.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.28 46.15%
2024
$-0.24 14.29%
Unlock
2025
$-0.26 8.33%
Unlock
2026
$0.15 157.69%
Unlock
2027
$0.44 193.33%
Unlock
2028
$0.91 106.82%
Unlock

P/E ratio

Current -8.35 431.85%
2024
-6.95 16.77%
Unlock
2025
-6.58 5.32%
Unlock
2026
11.27 271.28%
Unlock
2027
3.84 65.93%
Unlock
2028
1.87 51.30%
Unlock

Based on analysts' sales estimates for 2024, the Akebia Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.41 119.09%
2024
2.44 1.44%
Unlock
2025
2.37 3.12%
Unlock
2026
1.71 27.96%
Unlock
2027
1.20 29.64%
Unlock
2028
0.87 27.76%
Unlock

P/S ratio

Current 2.04 158.16%
2024
2.07 1.45%
Unlock
2025
2.00 3.12%
Unlock
2026
1.44 27.96%
Unlock
2027
1.01 29.64%
Unlock
2028
0.73 27.76%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today